Mihaela C. Cristea, MD
In the phase III SOLO-1 trial, olaparib (Lynparza) resulted in an unprecedented improvement in progression-free survival (PFS) as frontline maintenance therapy in women with BRCA
-positive advanced ovarian cancer. With 2 additional PARP inhibitors under investigation, the field is likely to see survival improvements on the same scale in the future by homing in on a wider scope of aberrations, explained Mihaela C. Cristea, MD.
... to read the full story